Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant CapeOx chemotherapy plus chemoradiotherapy versus chemoradiotherapy followed by surgery and chemotherapy in high‑risk rectal cancer
2005-005149-20Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine and oxaliplatin in rectal adenocarcinoma (2 arms), sponsored by Sanofi. Primary endpoint: Pathological complete response rate (ypT0N0). Started Jan 2006; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2005-005149-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005149-20.